Buparlisib in combination with fulvestrant for hormone-receptor positive/HER2-negative locally advanced or metastatic breast cancer
NIHR HSRIC
Record ID 32016000353
English
Authors' objectives:
Buparlisib is intended to be used in combination with fulvestrant as second line therapy following disease progression on aromatase inhibitors in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. If licensed, it will provide an additional treatment option for this patient group. Buparlilsib is a small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib does not currently have Marketing Authorisation in the EU for any indication.
Breast cancer is the most common cancer in the UK, accounting for 30% of all cancers in women. In 2012, there were 42,773 new cases of breast cancer in England. Breast cancer risk is strongly related to age, with 81% of cases occurring in women aged over 50 years. Approximately 5% of patients present with metastatic breast cancer, and around 30% of patients who present with localised disease will later develop metastases.
Current treatment options for postmenopausal women with advanced hormone receptor-positive/HER2-negative breast cancer include endocrine therapies (including tamoxifen, fulvestrant, everolimus), chemotherapy (including anthracycline-, taxane-, or platinum-based regimens), surgery and radiotherapy. Buparlisib with fulvestrant is currently in a phase III clinical trial comparing its effect on progression-free survival against treatment with placebo and fulvestrant. This trial is expected to complete in late 2015.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/buparlisib-in-combination-with-fulvestrant-for-hormone-receptor-positiveher2-negative-locally-advanced-or-metastatic-breast-cancer/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Breast Neoplasms
- Estradiol
- Fulvestrant
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.